The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder

CBG and Attention: A Double-Blind, Randomized, Placebo-Controlled Trial Examining the Effects of Cannabigerol on Indicators of Attention-Deficit/Hyperactivity Disorder

The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder (NCT06115603) is a Phase 2 interventional studying Attention-Deficit/Hyperactivity Disorder, sponsored by University of Arkansas, Fayetteville. RECRUITING as of the most recent ClinicalTrials.gov update. Talk to your doctor before contacting the trial site.

About This Trial

The goal of this clinical trial is to evaluate the effects of Cannabigerol (CBG) on indicators of Attention-Deficit/Hyperactivity Disorder (ADHD) in a sample of participants indicating/reporting symptoms associated with ADHD. The main question it aims to answer is: Does CBG reduce ADHD-related indicators relative to placebo? Participants will administer an acute dose of placebo or 80mg CBG and complete outcome measures at 45 minutes and 75 minutes. Daily surveys to monitor safety will be administered for one week following administration.

What Stage of Research Is This?

Phase 2 trials evaluate whether a treatment actually works against Attention-Deficit/Hyperactivity Disorder and continue monitoring side effects. Phase 2 enrolls larger groups (typically 100–300 patients) and produces the first real efficacy signal. A successful Phase 2 readout is what unlocks the much larger Phase 3 confirmatory trials needed for FDA approval.

This trial is currently recruiting participants. The sponsor has registered the study with ClinicalTrials.gov as actively enrolling, which means new applicants who meet the eligibility criteria can be considered for screening. Trial status can change between updates — confirm current recruiting status with the study contact before traveling for a screening visit.

Target enrollment of 76 participants puts this in the typical range for a Phase 2-style efficacy study or a moderate Phase 3 trial in a focused Attention-Deficit/Hyperactivity Disorder subpopulation. At this scale, the study has enough statistical power to detect a clear treatment effect but is not the largest cohort in the field.

Who May Be Eligible (Plain English)

These are translations of the protocol\'s inclusion and exclusion criteria, simplified for patients and caregivers. The original clinical text appears below. Eligibility is ultimately confirmed by the trial site\'s screening process — this summary is a starting point for a conversation with your doctor, not a final determination.

Original Eligibility Criteria

View original clinical language

1. Between 18 and 55-years-old. 2. BMI between 18 and 35 kg/m2. 3. Score a 4 or above on the Adult ADHD Self-Report Scale (ASRS-v1.1) Symptom Checklist Part A. 4. Meet diagnostic criteria for ADHD with a current severity rating of at least mild as defined by the DIAMOND. 5. Are not pregnant or currently breastfeeding. 6. Have no history of significant allergic condition, hypersensitivity, or allergic reactions to cannabis, cannabinoid medications, hemp products, medium chain triglyceride oil, or peppermint. 7. Have not used CBG or any other cannabinoid products in the past 30 days. 8. Willing to abstain from using cannabis or any THC-containing product for the duration of the study. 9. Have never used a synthetic cannabinoid or cannabinoid analogue (e.g., dronabinol, nabilone), or a synthetic cannabinoid receptor agonist (e.g., spice, k2). 10. Have not been exposed to any investigational drug or device 30 days prior to screening and you have no plans to take an investigational drug during the study. 11. Willing to maintain a stable treatment regimen (i.e., no change in current medication use) for the duration of the study. 12. Not currently taking a prescription medication for ADHD and have not been prescribed a medication for ADHD in the past six months. 13. Not currently having thoughts of committing suicide 14. Does not meet criteria for current severe major depressive disorder or a substance use disorder. 15. Have not been diagnosed with bipolar disorder or psychosis. 16. Do not have an acute illness, such as a respiratory infection or other illness that would interfere with study participation; not currently taking medication for an acute illness (e.g., antibiotic). 17. Do not have history of diagnosis related to liver function and/or significantly impaired liver function (e.g., cirrhosis of the liver, hepatitis). 18. Willing to ensure they have used effective contraception (for example, oral contraception, double barrier, intra-uterine device) for 30 prior to the study and for 30 days after study completion. 19. Have access to a ride to the University of Arkansas campus for research appointments. 20. Willing to comply with current university mandates as they pertain to COVID-19 protocols (e.g., mask wearing). 21. Do not have any serious or unstable physical health conditions including neurological or renal illness. 22. Do not have any current or historical cardiovascular conditions, including hypotension, bradycardia, or heart block. 23. No atrial fibrillation, bradycardia, or tachycardia detected via mobile electrocardiogram during the in-laboratory visit. 24. No recent illicit drug use other than cannabis, or alcohol use in the 12 hours preceding the in-laboratory visit. 25. Not currently prescribed or taking the following medications: * Warfarin * Clobazam * Valproic acid * Phenobarbital * Mechanistic Target of Rapamycin \[mTOR\] Inhibitors * Oral tacrolimus * St. John's wort * Epidiolex * Escitalopram * Cardiovascular medications * Strong CYP3A4 inhibitors (e.g., ketoconazole)

Treatments Being Tested

DRUG

Cannabigerol

1 mL of 80mg Cannabigerol once during experimental session

OTHER

Placebo

1 mL of placebo once during experimental session

Locations (1)

Trial sites listed on ClinicalTrials.gov for this study. Site activation status can vary — confirm with the specific site before traveling for a screening visit.

University of Arkansas

Fayetteville, Arkansas, United States

How to Talk to Your Doctor About This Trial

Bring the printable summary of this trial — including the NCT ID (NCT06115603), the sponsor (University of Arkansas, Fayetteville), and the key eligibility criteria — to your next appointment. Your doctor can review the inclusion and exclusion criteria against your medical history, lab values, and current treatments to assess whether you are likely to qualify. They can also help you weigh whether trial participation makes sense alongside your existing care plan.

Useful questions to walk through together: What does the trial protocol require beyond standard care? How long is the active treatment phase, and how long is follow-up? Are there study visits at sites I can reach? Who pays for the trial-specific procedures, and who pays for standard-of-care portions? See our 25 questions to ask about clinical trials guide for a more complete checklist.

Authoritative Sources

The official record for this trial lives on ClinicalTrials.gov — the federal registry maintained by the National Library of Medicine at NIH. For background on how this trial fits into the FDA approval pathway, see the FDA drug approval process. For oncology-specific guidance for patients considering trials, the National Cancer Institute publishes patient-oriented overviews. International trial registries are aggregated by the WHO ICTRP.

Frequently Asked Questions

What is the NCT06115603 clinical trial studying?

Who can participate in NCT06115603?

Eligibility for this trial depends on the specific inclusion and exclusion criteria set by the sponsor. The plain-English summary above translates the most important criteria into accessible language; the official clinical text is preserved in the collapsible section underneath. Whether you fit any specific trial is a medical decision your doctor needs to confirm — bring the trial information to your treating physician for a full review against your medical history.

How do I contact the trial site for NCT06115603?

Contact information registered with ClinicalTrials.gov is shown in the sidebar of this page. Before reaching out, confirm with your treating physician that this trial is appropriate for your situation. The trial site will then walk you through the screening process to determine final eligibility.

Is participating in a clinical trial safe?

Clinical trials in the United States are regulated by the FDA and overseen by Institutional Review Boards (IRBs) that review the protocol for safety. Risk varies by trial — Phase 1 studies test new treatments in humans for the first time, while Phase 3 trials use treatments that have already passed earlier safety screening. The informed consent document for any specific trial details the known risks and what to expect. Discuss those risks with your physician before deciding whether to participate.

Where can I verify the data on this page?

Every detail on this page comes directly from the ClinicalTrials.gov API. Click "View on ClinicalTrials.gov" in the sidebar to see the official, unmodified record. The federal record is always authoritative; this page is a structured presentation with a plain-English eligibility translation. For background on how clinical trials are regulated, see the FDA drug approval process documentation.

How This Page Is Built

Every field on this page is pulled directly from the ClinicalTrials.gov API v2 — no estimates, no proxies. The plain-English eligibility translation is generated from the original protocol text and reviewed for fidelity to the underlying clinical criteria. The original clinical text remains visible in the collapsible section above so users and clinicians can verify the translation. Read the full methodology for the data pipeline and known limitations.

Source: ClinicalTrials.gov API v2 record for NCT06115603. Maintained by the National Library of Medicine at NIH. Public domain. Cite as: "TrialFinderData. NCT06115603. Data: ClinicalTrials.gov."

Medical disclaimer: This page is informational, not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Last updated 2026-05-08 · Data from ClinicalTrials.gov.